Prostate cancer has a distinctly recognized pattern of metastases: multifocal and osteoblastic lesions involving the axial skeleton and non-calcified lymph nodes in the pelvic and lumbar aortic groups. Most adenocarcinomas are capable of producing macrocalcification. We report a case of prostate cancer with de novo calcified metastases to the liver and retroperitoneal lymph nodes mimicking the pattern usually seen in mucin-producing adenocarcinomas arising from the gastrointestinal tract. To our knowledge, this is the first such case to be reported in the literature. We propose a multifactorial mechanism that supports dystrophic calcification in this case. The knowledge of atypical presentation of metastatic disease can prevent diagnostic delay and prompt initiation of therapy.
A 61-year-old man presented to the emergency room with obstructive uropathy, generalized lymphadenopathy, liver mass and an elevated prostate-specific antigen (PSA) of 670 ng/ml. He was apparently healthy until 6 months prior when he noted progressive fatigue, weight loss of 30 pounds, loss of appetite and occasional nausea and vomiting that became more frequent in the 3 weeks before his presentation to the emergency room. Two months before admission he developed urinary hesitancy, frequency, urgency and bilateral flank pain. At the same time, he also noted a painless swelling in his right groin that progressively increased in size. The patient had no significant past medical history and had not sought routine primary health care during the last 10 years and had no prior prostate or colon cancer screening. His social history was significant for 30 pack-years of cigarette smoking. His family history was significant for his mother having gastric cancer at a young age, his twin brother having lung cancer and an older brother being diagnosed with prostate cancer at age 44 years.
Examination revealed profound pallor and non-tender hepatomegaly. A 2 Â 3 cm immobile, minimally tender, firm right inguinal lymph node was palpated. A digital rectal examination revealed a smooth enlarged prostate of approximately 60 g without any palpable nodules. A bedside stool Guaiac test for occult blood was positive. Laboratory tests were significant for normocytic anemia (hematocrit, 16.6%), hyperphosphatemia (13.3 mg/dl) and acute on chronic renal insufficiency (serum creatinine, 11.3 mg/dl; blood-ureanitrogen, 295 mg/dl). A urine analysis demonstrated pyuria and microscopic hematuria (2-5 red blood cells per high-power field).
Non-contrast computed tomography (CT) showed several liver lesions, the largest measured 6.1 Â 5.4 cm 2 . This heterogeneous mass contains coarse calcifications and central necrosis (Figure 1a ). There were also multiple enlarged retroperitoneal, pelvic and inguinal lymph nodes, most containing coarse calcifications. The largest left iliac lymph node measured 7.4 Â 3.4 cm 2 ( Figure 1b) . The kidneys showed bilateral moderate to severe hydronephrosis owing to obstruction from the large pelvic lymph nodes. A 1.9 Â 1.2 cm 2 soft tissue mass was noted adjacent and to the left of the rectum, raising the possibility of an underlying rectal mass. The urinary bladder was partially distended with a lobulated contour and wall thickening. The imaging study was interpreted as advanced carcinoma of unknown origin, mostly consistent with a mucinous adenocarcinoma, likely from a gastrointestinal source.
To help identify the primary cancer, serum tumor markers were obtained. Carcinoembryonic antigen was only mildly elevated at 4 ng/ml, whereas serum PSA level was greatly elevated at 670 ng/ml. Although the laboratory tests suggested a diagnosis of prostate cancer, the CT scan findings were atypical and the possibility of a second primary was postulated. Also, an adjacent rectal carcinoma infiltrating the prostate and thereby causing elevation in serum PSA was considered. This phenomenon has been described in leukemic infiltration of the prostate gland. 1 To obtain a definitive diagnosis, an excisional biopsy of the right inguinal lymph node was performed. Hematoxylin and eosin-stained sections showed complete effacement of the nodal architecture with moderately to poorly differentiated adenocarcinoma (Figure 2a and b) . Multiple foci of necrosis (arrow) with calcification (star) were identified. Immunohistochemical staining for CK7 was negative, CK20 weakly positive and PSA strongly positive (Figure 2c) , especially in the moderately differentiated areas. Overall, these findings confirmed a diagnosis of metastatic prostate cancer. A prostate biopsy was subsequently performed and revealed adenocarcinoma, Gleason grade 5 þ 4, with perineural invasion within both lobes. There were no detectable osseous metastases on a bone scan. Although the liver mass was not biopsied, it was presumed to be a metastasis from the patient's prostate cancer. Thus, the disease was cT2cN1M1, stage IV by AJCC guidelines (refer AJCC sixth edition). PCA with calcified metastases P Ghosh et al
The patient was started on antiandrogen therapy with bicalutamide (50 mg orally per day) followed by a luteinizing hormone-releasing hormone agonist, goserelin acetate (Zoladext). He subsequently underwent trans-urethral resection of the prostate and bilateral ureteral stenting, in an attempt to relieve his obstructive uropathy. The tumor responded favorably to androgen blockade as evidenced by decline in serum PSA to 30 ng/ ml at 6 months and by decrease in the size of the hepatic mass (Figure 3a and b) and the lymph nodes (Figure 3b ) on a concurrent CT scan. With the regression in size, an increase in calcification was observed within all the metastatic foci. At the last follow-up, 12 months after treatment initiation, he continues to have sustained response to hormonal therapy (last PSA 28 ng/ml).
Discussion
Patients presenting with widely metastatic carcinoma of an unknown primary, such as in this case, are not uncommon. Adenocarcinomas account for 70% of cases of carcinomas of unknown primary; identification of the primary tumor is frequently difficult. Serum tumor markers are of limited sensitivity and specificity in identifying the site of origin except for PSA, which is very specific for prostate. There are radiographic appearances or patterns that are more characteristic of certain primaries, but they too are also not highly sensitive or specific. The radiologic findings in this case of liver and lymph node masses with coarse calcification and necrosis suggest a mucin-producing adenocarcinoma, most likely from a gastrointestinal primary in a male of this age. Mucin-producing adenocarcinomas arising from ovary, breast, lung, pancreas and cervix can also have dystrophic calcification. Prostate cancer is known to undergo accelerated tumor necrosis and calcification after initiation of hormonal therapy; 2 however, de novo calcification has not been reported previously.
We propose a multifactorial mechanism for the presence of tumoral calcification in this case. First, dystrophic calcification occurs in damaged tissues when unresorbed necrotic material persists for prolonged periods. Abnormal calcium and inorganic phosphate homeostasis in apoptotic blebs and cellular degradation products form the nidi for calcification. Aggressive tumors with high cell turnover or tumors outgrowing vascular supply with resultant necrosis are therefore predisposed to calcification. In our patient, before therapy, there was significant necrosis and calcification within the lymph node and liver metastases, and the de novo calcification became increasingly prominent during the course of therapy (Figure 3a) . Secondly, metastatic calcification (calcium deposition in previously healthy tissues in hypercalcemic states) may also have played a role in this case: the calcium-phosphorus product was significantly elevated in this patient (B128 mg 2 /dl 2 ) owing to concurrent azotemia. As calcium in calcinosis is derived from serum and not from the necrotic tissue itself, it can be hypothesized that an elevated calciumphosphorus product would help initiate/augment the deposition of Ca-phosphate. Finally, the role of mucin in calcification cannot be neglected. Most adenocarcinomas (prostate included) secrete acidic mucins, with sialomucins predominating over sulfomucins. In the case of prostate, well differentiated and moderately differentiated tumors are not O-acylated. The poorly differentiated ones (as in our patient) characteristically have C9-O-acylated sialomucins resembling those secreted by mucinous adenocarcinomas of gastrointestinal and ovarian origin. 3, 4 O-acetylation is likely associated with increase in pKa (the negative logarithm of the acid dissociation constant, Ka) of the sialomucins, rendering them less acidic, favoring deposition of Ca-phosphate. These three factors (elevated calciumphosphate product, increased necrosis and O-acetylation of sialomucins) could govern formation of dystrophic calcification in any adenocarcinoma, and interplay of all three factors might be more important rather than the presence of any one.
In conclusion, this case report bears the following learning points: (a) prostate cancer may present with unusual calcified metastases, the knowledge of which is necessary for accurate diagnoses; (b) the development of de novo calcification may be multifactorial, suggesting aggressiveness and poorer differentiation of the tumor, thus an overall dismal prognosis. Figure 1a) . (b) Tumor response to therapy assessed by serial serum prostate-specific antigen (Y1-axis) and radiographic size of metastases (Y2-axis) were plotted against duration of therapy (X-axis).
PCA with calcified metastases P Ghosh et al
